These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28314294)

  • 1. Mismatch Repair Protein Deficiency Is a Risk Factor for Aberrant Expression of HLA Class I Molecules: A Putative "Adaptive Immune Escape" Phenomenon.
    Kubo T; Hirohashi Y; Matsuo K; Sonoda T; Sakamoto H; Furumura K; Tsukahara T; Kanaseki T; Nakatsugawa M; Hirano H; Furuhata T; Takemasa I; Hasegawa T; Torigoe T
    Anticancer Res; 2017 Mar; 37(3):1289-1295. PubMed ID: 28314294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer.
    Mariya T; Kubo T; Hirohashi Y; Yanagawa J; Tabuchi Y; Matsuo K; Furumura K; Morita R; Nakatsugawa M; Kanaseki T; Tsukahara T; Hasegawa T; Saito T; Torigoe T
    Med Mol Morphol; 2021 Mar; 54(1):14-22. PubMed ID: 32410009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas.
    de Jong RA; Boerma A; Boezen HM; Mourits MJ; Hollema H; Nijman HW
    Int J Cancer; 2012 Oct; 131(8):1828-36. PubMed ID: 22287095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer.
    Hanagiri T; Shigematsu Y; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Nagata Y; Baba T; Uramoto H; So T; Yamada S
    Anticancer Res; 2013 May; 33(5):2123-8. PubMed ID: 23645764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
    de Vries NL; van de Haar J; Veninga V; Chalabi M; Ijsselsteijn ME; van der Ploeg M; van den Bulk J; Ruano D; van den Berg JG; Haanen JB; Zeverijn LJ; Geurts BS; de Wit GF; Battaglia TW; Gelderblom H; Verheul HMW; Schumacher TN; Wessels LFA; Koning F; de Miranda NFCC; Voest EE
    Nature; 2023 Jan; 613(7945):743-750. PubMed ID: 36631610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HLA class I antigens in sporadic adenomas and histologically normal mucosa of the colon.
    Tsioulias GJ; Triadafilopoulos G; Goldin E; Papavassiliou ED; Rizos S; Bassioukas P; Rigas B
    Cancer Res; 1993 May; 53(10 Suppl):2374-8. PubMed ID: 8485724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression.
    Dierssen JW; de Miranda NF; Ferrone S; van Puijenbroek M; Cornelisse CJ; Fleuren GJ; van Wezel T; Morreau H
    BMC Cancer; 2007 Feb; 7():33. PubMed ID: 17316446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
    Seliger B; Ferrone S
    Methods Mol Biol; 2020; 2055():325-350. PubMed ID: 31502159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies.
    Yie SM; Hu Z
    Histol Histopathol; 2011 Mar; 26(3):409-20. PubMed ID: 21210353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency.
    Jensen LH; Lindebjerg J; Byriel L; Kolvraa S; Crüger DG
    Colorectal Dis; 2008 Jun; 10(5):490-7. PubMed ID: 17868408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
    Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
    Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of HLA class I expression in patients with colorectal cancer.
    Iwayama Y; Tsuruma T; Mizuguchi T; Furuhata T; Toyota N; Matsumura M; Torigoe T; Sato N; Hirata K
    World J Surg Oncol; 2015 Feb; 13():36. PubMed ID: 25889416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.
    Levy EM; Sycz G; Arriaga JM; Barrio MM; von Euw EM; Morales SB; González M; Mordoh J; Bianchini M
    Innate Immun; 2009 Apr; 15(2):91-100. PubMed ID: 19318419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of HLA class I molecules in the immune escape of urologic tumors.
    Carretero R; Gil-Julio H; Vázquez-Alonso F; Garrido F; Castiñeiras J; Cózar JM
    Actas Urol Esp; 2014 Apr; 38(3):192-9. PubMed ID: 24315763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
    Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
    Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.
    Liu SS; Yang YZ; Jiang C; Quan Q; Xie QK; Wang XP; He WZ; Rong YM; Chen P; Yang Q; Yang L; Zhang B; Xia XJ; Kong PF; Xia LP
    J Transl Med; 2018 Jul; 16(1):195. PubMed ID: 30005666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.